Lanicemine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Lanicemine
Lanicemine.svg
Lanicemine ball-and-stick model.png
Clinical data
ATC code
  • none
Legal status
Legal status
  • Development terminated
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
Chemical and physical data
Formula C13H14N2
Molar mass 198.26 g/mol
3D model (JSmol)

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression.[1][2] Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects.[3] However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.[4]

See also[edit]

References[edit]

  1. ^ "Lanicemine". AdisInsight. Retrieved 18 June 2017. 
  2. ^ Machado-Vieira, R; Henter, ID; Zarate CA, Jr (May 2017). "New targets for rapid antidepressant action.". Progress in neurobiology. 152: 21–37. PMC 4919246Freely accessible. PMID 26724279. doi:10.1016/j.pneurobio.2015.12.001. 
  3. ^ Zarate, C. A.; Mathews, D.; Ibrahim, L.; Chaves, J. F.; Marquardt, C.; Ukoh, I.; Jolkovsky, L.; Brutsche, N. E.; Smith, M. A.; Luckenbaugh, D. A. (2012). "A Randomized Trial of a Low-Trapping Nonselective N-Methyl-D-Aspartate Channel Blocker in Major Depression". Biological Psychiatry. 74 (4): 257–264. PMC 3594049Freely accessible. PMID 23206319. doi:10.1016/j.biopsych.2012.10.019. 
  4. ^ Flowers, Sophie. "Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company". Retrieved 6 February 2014.